Original Research
Feb 18
Stefan Verheye, Johan Bennett, et al.
The PINNACLE-I trial demonstrated the safety and effectiveness of the Hertz Contact Intravascular Lithotripsy (HC-IVL) device in facilitating and optimizing coronary stent implantation in patients with calcified lesions.
open access
Flashlight
Feb 17
Fabian Barbieri, Markus Reinthaler, et al.
An 81-year-old male patient with severe, functional tricuspid regurgitation underwent a novel transcutaneous implantation of a spacer device (Pivot Extend), resulting in a reduction in TR severity and improvement in right ventricular function.
open access
new issue
Feb 16
A State-of-the-Art on adjunctive pharmacological strategies for residual risk; a consensus statement on day-case PCI; aspirin discontinuation timing in ACS; 7-year outcomes in COMPARE-ABSORB; the PINNACLE-I trial; a novel spacer for tricuspid regurgitation treatment; news from PCR; and more
Viewpoint
Feb 16
Bernard Prendergast
PCR announces a new era, with an expanded educational mission and commitment to advancing interventional cardiology through education, research, and innovation under a new leadership team.
free
Research Correspondence
Feb 13
Róbert Bellavics, Zoltan Ruzsa, et al.
This study compared the safety and efficacy of two closure devices, StatSeal and TR Band, for distal foot artery access site closure in 150 patients undergoing lower-limb endovascular interventions. Both devices showed low access site complication rates.
Original Research
Feb 11
Gilbert H.L. Tang, Michael J. Reardon, et al.
This single-arm study evaluated the 5-year outcomes of the early-generation Intrepid transapical transcatheter mitral valve replacement system in high-risk patients with symptomatic ≥moderate-severe mitral regurgitation, observing sustained mitral regurgitation reduction and durable valve performance among survivors.
Editorial
Feb 12
Marianna Adamo, Elisa Pezzola
The content discusses the use of transcatheter edge-to-edge repair (TEER) for the treatment of mitral regurgitation, with data on patient characteristics, outcomes, and safety profiles.
free
Flashlight
Feb 9
Masakazu Yasuda, Gaku Nakazawa, et al.
A 71-year-old male with schizophrenia and chronic subdural hematoma underwent urgent TAVI using a 26 mm SAPIEN 3 valve via left subclavian access. Prosthesis-balloon alignment failure and balloon rupture occurred, requiring retrieval of the stuck prosthesis and delivery system via the left ventricular apex.
open access
Original Research
Feb 10
Stefano Cannata, Azeem Latib, et al.
This study compared the outcomes of TAVI using the self-expanding Navitor and balloon-expandable SAPIEN 3 Ultra transcatheter heart valves in patients with small aortic annuli. The Navitor device showed better hemodynamic performance but higher rates of mild paravalvular leak and permanent pacemaker implantation.
Research Correspondence
Feb 9
Yingyang Geng, Lei Song, et al.
This retrospective study found that left-dominant patients undergoing PCI for left main disease had a higher risk of long-term adverse events, particularly target vessel revascularization, compared to non-left-dominant patients.
Research Correspondence
Feb 5
Tim Wittig, Sabine Steiner, et al.
The COMPARE trial found no significant difference in 5-year clinically driven target lesion revascularization rates between low-dose and high-dose paclitaxel-coated balloons for the treatment of femoropopliteal lesions in patients with lower limb peripheral artery disease.
Expert Review
Feb 4
Sergio Berti, Ralph Stephan von Bardeleben, et al.
This expert review discusses the growing importance of intracardiac echocardiography (ICE), particularly 3D ICE, in guiding structural heart interventions due to its ability to provide high-resolution imaging of cardiac anatomy.
free
Editorial
Feb 3
Francesco Maisano
The content discusses the evolution and future of transcatheter aortic valve implantation (TAVI) in the management of aortic stenosis, highlighting the need for further innovation to address unmet needs and enable better lifetime management of patients.
free
Original Research
Feb 2
Ole De Backer, Vinayak N. Bapat, et al.
The novel DurAVR transcatheter heart valve demonstrated high technical success, favorable 30-day clinical and hemodynamic outcomes, and a low rate of complications in patients with small aortic annuli.
open access
